MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2012-09-25
Last Posted Date
2023-06-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
347
Registration Number
NCT01691859
Locations
🇬🇧

GSK Investigational Site, Southampton, United Kingdom

RELOVAIR® Lung Deflation Study

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2012-09-25
Last Posted Date
2016-10-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
45
Registration Number
NCT01691885
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

A Study in Adolescent Females to Explore Cytomegalovirus Infection

Not Applicable
Completed
Conditions
Infections, Cytomegalovirus
Interventions
Procedure: Blood collection
Procedure: Urine collection
Procedure: Saliva collection
First Posted Date
2012-09-25
Last Posted Date
2021-04-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
369
Registration Number
NCT01691820
Locations
🇲🇽

GSK Investigational Site, Jojutla, Morelos, Mexico

Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

Phase 2
Completed
Conditions
Dentine Hypersensitivity
Interventions
First Posted Date
2012-09-24
Last Posted Date
2014-05-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
140
Registration Number
NCT01691560
Locations
🇺🇸

BioSci Research America, Las Vegas, Nevada, United States

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: OCS (prednisone/prednisolone)
First Posted Date
2012-09-24
Last Posted Date
2017-03-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
135
Registration Number
NCT01691508
Locations
🇬🇧

GSK Investigational Site, Southampton, United Kingdom

ARIXTRA® Adherence in SVT Patients.

Completed
Conditions
Thrombosis, Venous
Interventions
First Posted Date
2012-09-24
Last Posted Date
2015-03-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1
Registration Number
NCT01691495

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: SC Placebo
Drug: IV Placebo
First Posted Date
2012-09-24
Last Posted Date
2018-08-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
580
Registration Number
NCT01691521
Locations
🇬🇧

GSK Investigational Site, Southampton, United Kingdom

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Albuterol/salbutamol
First Posted Date
2012-09-24
Last Posted Date
2018-06-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
56
Registration Number
NCT01691482
Locations
🇬🇧

GSK Investigational Site, Manchester, United Kingdom

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: UMEC /VI
Drug: VI
Drug: UMEC
Drug: FF
First Posted Date
2012-09-24
Last Posted Date
2017-07-26
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
44
Registration Number
NCT01691547
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender

Phase 1
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
Other: GSK2586184 single dose taken without food
Drug: GSK2586184 800mg single and repeat dose
Drug: Placebo-to-match GSK2586184
Other: GSK2586184 single dose taken with food
First Posted Date
2012-09-18
Last Posted Date
2018-05-25
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
19
Registration Number
NCT01687309
Locations
🇧🇪

GSK Investigational Site, Antwerpen, Belgium

© Copyright 2025. All Rights Reserved by MedPath